Our top line performance, coupled with the ongoing capture of operational synergies, supported investments into strategic growth drivers, while delivering adjusted earnings per share above our guidance range. The firm had revenue of $1.93 billion for the quarter, compared to the consensus estimate of $1.90 billion.
Advertisement
While if we look at the Earnings Track Record, Zimmer Biomet Holdings, Inc. The consensus price target of $129.48 means that the market expects Company shares to increase by 4.97% in the short run. The 7 months bullish chart indicates low risk for the $25.26 billion company.
The stock’s price switched up -0.53% 20-Days Simple Moving Average, added 1.50% from 50-Days Simple Moving Average and positively 14.37% from 200 Days Simple Moving Average. The debt-to-equity ratio (D/E) was recorded at 0.00. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.78%. Guggenheim has been covering shares of ZBH, so it’s most recent view is worth a look.
Zimmer Biomet Holdings, Inc.
Zimmer Biomet Holdings Inc has moved 2.39% above its 50-day simple moving average of $121.05 and went up 15.40% from its 200-day simple moving average of $110.47. Zimmer Biomet Holdings has been the topic of 16 analyst reports since August 27, 2015 according to StockzIntelligence Inc. The sell-side target prices range from $91 to $150. Wall Street analysts on the average recommend the company shares as Overweight. In a research note released on June 09, 2016, analysts at Guggenheim issued its first rating on the stock at Neutral.
Advertisement
Trade-Ideas LLC identified Zimmer Biomet Holdings (ZBH) as a new lifetime high candidate. Its RSI (Relative Strength Index) reached 52.08. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In contrast, the average volume was 1604870 shares. The disclosure for this sale can be found here. “Zimmer Biomet Holdings, Inc., formerly known as Zimmer Holdings, Inc., is based in Warsaw, United States”.
